Sana Biotechnology Maintains Buy Recommendation from HC Wainwright & Co. with 105.08% Upside Potential

HC Wainwright & Co. maintains a Buy recommendation for Sana Biotechnology (SANA) with a target price of $8.31/share, a 105.08% increase from its latest closing price. The firm projects annual revenue of $0MM and non-GAAP EPS of -$1.95. The average portfolio weight of all funds dedicated to SANA is 0.14%, and total shares owned by institutions decreased by 2.04% to 161,168K shares.